Key result
Pharmacological management to slow or halt the progression of degenerative aortic stenosis remains elusive, though emerging agents and novel treatment strategies are currently under investigation.
Why the study?
Aortic valve replacement remains the only treatment for degenerative aortic stenosis, and effective medical therapies to slow or halt disease progression have remained elusive.
Does pharmacological management prevent or slow the progression of degenerative aortic stenosis?
Does pharmacological management prevent or slow the progression of degenerative aortic stenosis?
Despite promising observational data, effective medical therapy to slow or halt the progression of degenerative aortic stenosis remains elusive, prompting ongoing research into novel agents.
Degenerative aortic stenosis is a growing clinical problem owing to the high incidence in an aging population and its significant morbidity and mortality. Currently, aortic valve replacement remains the only treatment. Despite promising observational data, pharmacological management to slow or halt progression of aortic stenosis has remained elusive. Nevertheless, with a greater understanding of the mechanisms which underpin aortic stenosis, research has begun to explore novel treatment strategies. This review will explore the historical agents used to manage aortic stenosis and the emerging agents that are currently under investigation.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2023) conducted a review in Degenerative aortic stenosis. Pharmacological management was evaluated. Pharmacological management to slow or halt the progression of degenerative aortic stenosis remains elusive, though emerging agents and novel treatment strategies are currently under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: